Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer

Open access

Abstract

At the MONARCH 3 interim analysis, abemaciclib plus a nonsteroidal aromatase inhibitor (AI) significantly improved progression-free survival (PFS) and objective response rate (ORR) with a tolerable safety profile as initial treatment for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC). MONARCH 3 is a randomized, phase III, double-blind study of abemaciclib/placebo (150 mg twice daily, continuous) plus nonsteroidal AI (1 mg anastrozole or 2.5 mg letrozole, daily). A total of 493 postmenopausal women with HR+, HER2− ABC with no prior systemic therapy in this setting were enrolled. The primary endpoint was investigator-assessed PFS (final analysis after 240 events); other endpoints included response and safety evaluations. Here we analyze the final PFS data and update secondary endpoints. The abemaciclib arm had a significantly longer median PFS than the placebo arm (28.18 versus 14.76 months; hazard ratio [95% confidence interval], 0.540 [0.418–0.698]; p = .000002). The ORR was 61.0% in the abemaciclib arm versus 45.5% in the placebo arm (measurable disease, p = .003). The median duration of response was longer in the abemaciclib arm (27.39 months) compared to the placebo arm (17.46 months). The safety profile was consistent with previous reports. The most frequent grade ≥ 3 adverse events in the abemaciclib versus placebo arms were neutropenia (23.9% versus 1.2%), diarrhea (9.5% versus 1.2%), and leukopenia (8.6% versus 0.6%). Abemaciclib plus a nonsteroidal AI was an effective initial treatment with an acceptable safety profile for HR+, HER2− ABC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41523-018-0097-z

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Progression-free survival. a Investigator-assessed and b Independent central review in the intent-to-treat population. NR, not reached
Fig. 1 Progression-free survival. a Investigator-assessed and b Independent central review in the intent-to-treat population. NR, not reachedCC BY · PubMed Central
Fig. 2 Subgroup analysis of progression-free survival. ECOG PS, Eastern Cooperative Oncology Group Performance Status
Fig. 2 Subgroup analysis of progression-free survival. ECOG PS, Eastern Cooperative Oncology Group Performance StatusCC BY · PubMed Central
Fig. 3 Tumor response for patients with measurable disease. a Best percent change in tumor size. b Mean: percentage change in tumor size from baseline by cycle
Fig. 3 Tumor response for patients with measurable disease. a Best percent change in tumor size. b Mean: percentage change in tumor size from baseline by cycleCC BY · PubMed Central
Fig. 4 Patient response to treatment. a Median time to response for patients with measurable disease (investigator assessment). b Duration of response. c Probability of response in patients with measurable disease
Fig. 4 Patient response to treatment. a Median time to response for patients with measurable disease (investigator assessment). b Duration of response. c Probability of response in patients with measurable diseaseCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Cited by

See all 685

Metadata

Authors
Johnston, S., Martin, M., Di Leo, A., Im, S.-A., Awada, A., Forrester, T., Frenzel, M., Hardebeck, M. C., Cox, J., Barriga, S., Toi, M., Iwata, H., & Goetz, M. P.
Affiliations
  • Royal Marsden NHS Foundation Trust (GB)
  • Seoul National University (KR)
  • Université Libre de Bruxelles (BE)
  • Eli Lilly (United States) (US)
  • Eli Lilly (United Kingdom) (GB)
  • Eli Lilly (Spain) (ES)
  • Kyoto University (JP)
  • Aichi Cancer Center (JP)
  • Mayo Clinic (US)
Corresponding author
Johnston, Stephen
Venue
npj Breast Cancer
Published
2019-01-17
Volume
5
Issue
1
Pages
5-5
ISSN
2374-4677 (ISSN-L)
OpenAlex
W2910972034
Cited by
685
References
30
Citations by year
2026: 58 · 2025: 127 · 2024: 121 · 2023: 111 · 2022: 78 · 2021: 88 · 2020: 72 · 2019: 25
FWCI
48.35
Type
journal article
Language
en
Open access
Licence
Locations
  • npj Breast Cancer (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Seoul National University Open Repository (Seoul National University) (submittedVersion)
Funders
Eli Lilly and Company
Topics
  • Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Keywords
abemaciclib, advanced breast cancer, hormone receptor-positive breast cancer, HER2-negative breast cancer, nonsteroidal aromatase inhibitors, anastrozole, letrozole, progression-free survival, objective response rate, duration of response, CDK4/6 inhibitors, initial treatment, neutropenia, drug safety

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. https://app.cochat.ai/papers/10.1038/s41523-018-0097-z
The paper
Johnston, S., Martin, M., Di Leo, A., Im, S.-A., Awada, A., Forrester, T., Frenzel, M., Hardebeck, M. C., Cox, J., Barriga, S., Toi, M., Iwata, H., & Goetz, M. P. (2019). MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. npj Breast Cancer. https://doi.org/10.1038/s41523-018-0097-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.